NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

RPP decision paper

Review of TA298; Ranibizumab for treating choroidal neovascularisation associated with pathological myopia

Final recommendation post consultation
The guidance should be transferred to the 'static guidance list'.

1. Background

This guidance was issued in November 2013.

At the GE meeting of 19 July 2016 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance list'.

3. Rationale for selecting this proposal

Limited new evidence has been published since Technology Appraisal 298, and no evidence has been identified that suggests a review of this guidance is necessary.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

Respondent: Royal College of Ophthalmologists **Response to proposal:** Agree The College agrees that it would be appropriate to move this guidance to the static list. There are currently two licensed treatments for pathological myopia, Ranibizumab and Aflibercept and both are effective and approved by NICE.	**Comment from Technology Appraisals** Thank you for your comments.

Respondent: RNIB **Response to proposal:** Agree We agree to move the existing guidance TA298 to the static list as there is currently no evidence/study that is likely to lead to a change in the present guidelines.	**Comment from Technology Appraisals** Thank you for your comments.

Respondent: Bayer **Response to proposal:** Agree Bayer agrees with the recommendation to transfer this guidance to the static list.	**Comment from Technology Appraisals** Thank you for your comments.

Respondent: Novartis **Response to proposal:** Agree We agree with the guidance executive's proposal to move the guidance to the static list. We note the following information which requires correction: • On page 2 of Appendix B- GE proposal paper, the text states 'There have been no changes to ranibizumab since publication of TA283'. • On page 7, the price of a vial of ranibizumab is listed as £742.00. Please note, the public list price for Lucentis was changed to £551.00 per vial[1], effective 14th June 2016. The list price alteration does not impact the Patient Access Scheme (PAS), so the NHS purchase price is unchanged. **Reference** 1) Monthly Index of Medical Specialities (MIMS) (2016). Available at: http://www.mims.co.uk Accessed: 23 August 2016.	**Comment from Technology Appraisals** Thank you for your comments and for notifying us of the factual inaccuracies in the proposal paper – the version published on the NICE website will be updated to include the list price change.

Paper signed off by: Jenniffer Prescott, 30 September 2016

Contributors to this paper:

Technical Lead: Sophie Cooper

Programme Manager: Andrew Kenyon